The same approach was taken when the drug name description did not specify whether the cartridge size was 1.5 ml or 3 ml (when these were the only cartridge ... of the other PCAs for any year. These ...

Furthermore, Novo Nordisk should earn important label expansions for some of its current medicines while developing new ones in other areas. Semaglutide is being tested in Alzheimer's disease. And the ...

The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout ...

The stock fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of GLP-1 obesity drugs. Front and center of this is Novo Nordisk (NYSE: NVO), ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight loss drugs Ozempic and Wegovy, have been absolutely plummeting. The company's stock price slid over ...

Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.

Weight loss leader Novo Nordisk has had a poor performance at the stock markets year-to-date [YTD] even as the healthcare sector is among the least impacted ones. The key reason for this is ...

https://www.tipranks.com/news/the-fly/novo-nordisk-warns-of-counterfeit-ozempic-injections Novo Nordisk (NVO) said it has become aware of several hundred units of ...

Analyst downgrades Novo Nordisk, cuts price target to $64. The analyst highlights that Lilly's drugs, Mounjaro and Zepbound, will gain U.S. market share from Novo Nordisk's Ozempic and Wegovy.

The popularity of Novo Nordisk's Ozempic and Wegovy has attracted competitors and created supply constraints. Novo Nordisk's next-generation weight loss drug disappointed investors in Phase III ...